Clinical targeting recombinant immunotoxins for cancer therapy

References

• MooltenFLCooperbandSRSelective destruction of target cells by diphtheria toxin conjugated to antibody directed against antigens on the cellsScience1970169394068704986716
   PubMedGoogle Scholar
• KrolickKAVillemezCIsaksonPUhrJWVitettaESSelective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricinProc Natl Acad Sci U S A198077954196968912
   PubMed Web of Science ®Google Scholar
• CawleyDBHerschmanHRGillilandDGCollierRJEpidermal growth factor-toxin A chain conjugates: EGF-ricin A is a potent toxin while EGF-diphtheria fragment A is nontoxicCell19802225635706256086
   PubMedGoogle Scholar
• CarrollSFCollierRJActive site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxinJ Biol Chem198726218870787112885323
   PubMedGoogle Scholar
• PhanLDPerentesisJPBodleyJWSaccharomyces cerevisiae elongation factor 2. Mutagenesis of the histidine precursor of diphthamide yields a functional protein that is resistant to diphtheria toxinJ Biol Chem199326812866586688473309
   PubMedGoogle Scholar
• AlluredVSCollierRJCarrollSFMcKayDBStructure of exotoxin A of Pseudomonas aeruginosa at 3.0-Angstrom resolutionProc Natl Acad Sci U S A1986835132013243006045
   PubMed Web of Science ®Google Scholar
• HwangJFitzgeraldDJAdhyaSPastanIFunctional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coliCell19874811291363098436
   PubMedGoogle Scholar
• HesslerJLKreitmanRJAn early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptorBiochemistry (Mosc)199736471457714582
   Google Scholar
• KounnasMZMorrisREThompsonMRFitzGeraldDJStricklandDKSaelingerCBThe alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin AJ Biol Chem19922671812420124231618748
   PubMedGoogle Scholar
• ChironMFFrylingCMFitzGeraldDJCleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liverJ Biol Chem19942692718167181768027078
   PubMed Web of Science ®Google Scholar
• McKeeMLFitzGeraldDJReduction of furin-nicked Pseudomonas exotoxin A: an unfolding storyBiochemistry (Mosc)199938501650716513
   Google Scholar
• KreitmanRJPastanIImportance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptorBiochem J1995307129377717988
   PubMedGoogle Scholar
• ChaudharyVKJinnoYFitzGeraldDPastanIPseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicityProc Natl Acad Sci U S A19908713083122104981
   PubMedGoogle Scholar
• TheuerCKasturiSPastanIDomain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomesBiochemistry (Mosc)1994331958945900
   Google Scholar
• TheuerCPBuchnerJFitzGeraldDPastanIThe N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertionProc Natl Acad Sci U S A19939016777477788356083
   PubMedGoogle Scholar
• Keppler-HafkemeyerAKreitmanRJPastanIApoptosis induced by immunotoxins used in the treatment of hematologic malignanciesInt J Cancer2000871869410861457
   PubMed Web of Science ®Google Scholar
• BrinkmannUBrinkmannEGalloMPastanICloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1Proc Natl Acad Sci U S A1995922210427104317479798
   PubMed Web of Science ®Google Scholar
• RolfJMGaudinHMEidelsLLocalization of the diphtheria toxin receptor-binding domain to the carboxyl-terminal Mr approximately 6000 region of the toxinJ Biol Chem199026513733173372332431
   PubMed Web of Science ®Google Scholar
• ChoeSBennettMJFujiiGThe crystal structure of diphtheria toxinNature199235763752162221589020
   PubMed Web of Science ®Google Scholar
• WilliamsDPWenZWatsonRSBoydJStromTBMurphyJRCellular processing of the interleukin-2 fusion toxin DAB486-IL-2 and efficient delivery of diphtheria fragment A to the cytosol of target cells requires Arg194J Biol Chem19902653320673206772243114
   PubMedGoogle Scholar
• D’SilvaPRLalaAKUnfolding of diphtheria toxin identification of hydrophobic sites exposed on lowering of pH by photolabelingJ Biol Chem19982732616216162229632679
   PubMedGoogle Scholar
• KaulPSilvermanJShenWHRoles of Glu 349 and Asp 352 in membrane insertion and translocation by diphtheria toxinProtein Sci1996546876928845758
   PubMed Web of Science ®Google Scholar
• WilsonBABlankeSRReichKACollierRJActive-site mutations of diphtheria toxin. Tryptophan 50 is a major determinant of NAD affinityJ Biol Chem19942693723296233018083236
   PubMed Web of Science ®Google Scholar
• BennettMJEisenbergDRefined structure of monomelic diphtheria toxin at 2.3 A resolutionProtein Sci199439146414757833808
   PubMedGoogle Scholar
• YamaizumiMMekadaEUchidaTOkadaYOne molecule of diphtheria toxin fragment a introduced into a cell can kill the cellCell1978151245250699044
   PubMed Web of Science ®Google Scholar
• MattooARFitzgeraldDJCombination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell linesInt J Cancer2013132497898722821746
   PubMedGoogle Scholar
• TrainiRBen-JosefGPastranaDVABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of Pseudomonas exotoxin-based proteins to the cell cytosolMol Cancer Ther2010972007201520587662
   PubMedGoogle Scholar
• MorimotoHBonavidaBDiphtheria toxin- and Pseudomonas A toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alphaJ Immunol19921496208920941517572
   PubMedGoogle Scholar
• KochiSKCollierRJDNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesisExp Cell Res199320812963028359223
   PubMedGoogle Scholar
• Keppler-HafkemeyerABrinkmannUPastanIRole of caspases in immunotoxin-induced apoptosis of cancer cellsBiochemistry1998374816934169429836586
   PubMed Web of Science ®Google Scholar
• JenkinsCESwiatoniowskiAIssekutzACLinT-JPseudomonas aeruginosa exotoxin A induces human mast cell apoptosis by a caspase-8 and -3-dependent mechanismJ Biol Chem200427935372013720715205454
   PubMedGoogle Scholar
• DeckerTOelsnerMKreitmanRJInduction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxinsBlood200410372718272614525789
   PubMedGoogle Scholar
• BolognesiAPolitoLTazzariPLIn vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteinsBr J Haematol2000110235136110971392
   PubMedGoogle Scholar
• WalshMJDoddJEHautbergueGMRibosome-inactivating proteinsVirulence20134877478424071927
   PubMed Web of Science ®Google Scholar
• ConcanavalinAGelonin, a new inhibitor of protein synthesis, nontoxic to intact cellsJ Biol Chem198025514694769537391060
   PubMedGoogle Scholar
• EndoYMitsuiKMotizukiMTsurugiKThe mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes. The site and the characteristics of the modification in 28 S ribosomal RNA caused by the toxinsJ Biol Chem198726212590859123571242
   PubMed Web of Science ®Google Scholar
• WescheJRapakAOlsnesSDependence of ricin toxicity on translocation of the toxin A-chain from the endoplasmic reticulum to the cytosolJ Biol Chem199927448344433444910567425
   PubMedGoogle Scholar
• FossFMDAB 389 IL-2 (ONTAK): a novel fusion toxin therapy for lymphomaClin Lymphoma20001211011611707818
   PubMedGoogle Scholar
• OlsenEDuvicMFrankelAPivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphomaJ Clin Oncol200119237638811208829
   PubMed Web of Science ®Google Scholar
• PrinceHMDuvicMMartinAPhase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphomaJ Clin Oncol201028111870187720212249
   PubMed Web of Science ®Google Scholar
• PrinceHMMartinAGOlsenEAFivensonDPDuvicMDenileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndromeLeuk Lymphoma2013541697522738414
   PubMed Web of Science ®Google Scholar
• DannullJSuZRizzieriDEnhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJ Clin Invest2005115123623363316308572
   PubMed Web of Science ®Google Scholar
• BarnettBKryczekIChengPZouWCurielTJRegulatory T cells in ovarian cancer: biology and therapeutic potentialAm J Reprod Immunol200554636937716305662
   PubMed Web of Science ®Google Scholar
• MahnkeKSchönfeldKFondelSDepletion of CD4+ CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitroInt J Cancer2007120122723273317315189
   PubMed Web of Science ®Google Scholar
• MorseMAHobeikaACOsadaTDepletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccinesBlood2008112361061818519811
   PubMed Web of Science ®Google Scholar
• RaskuMAClemALTelangSTransient T cell depletion causes regression of melanoma metastasesJ Transl Med200861118171482
   PubMedGoogle Scholar
• Sue McCannMSNAkilovOEGeskinLAdverse effects of denileukin diftitox and their management in patients with cutaneous T-cell lymphomaClin J Oncol Nurs2012165E16423022942
   PubMedGoogle Scholar
• RobbRJRuskCMNeeperMPStructure-function relationships for the interleukin 2 receptor: location of ligand and antibody binding sites on the Tac receptor chain by mutational analysisProc Natl Acad Sci U S A19888515565456583135551
   PubMedGoogle Scholar
• KreitmanRJBailonPChaudiharyVKFitzGeraldDJPPastanIRecombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinomaBlood19948324264348286741
   PubMedGoogle Scholar
• KrietmanRJChaudharyVKWaldmannTWillinghamMCFitzGeraldDJPastanIThe recombinant immunotoxin anti-Tac (Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemiaProc Natl Acad Sci U S A19908721829182952236041
   PubMedGoogle Scholar
• KreitmanRJChaudharyVKWaldmannTACytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemiaLeukemia1993745535628464234
   PubMedGoogle Scholar
• SaitoTKreitmanRJHanadaSCytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptorCancer Res1994544105910648313362
   PubMedGoogle Scholar
• KreitmanRJBatraJKSeetharamSChaudharyVKFitzGeraldDJPastanISingle-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bondsBioconjug Chem1993421121207873642
   PubMedGoogle Scholar
• KreitmanRJPastanITargeting Pseudomonas exotoxin to hematologic malignanciesSemin Cancer Biol199565297306 Elsevier8562907
   PubMedGoogle Scholar
• KreitmanRJWilsonWHRobbinsDResponses in refractory hairy cell leukemia to a recombinant immunotoxinBlood199994103340334810552943
   PubMed Web of Science ®Google Scholar
• KreitmanRJWilsonWHWhiteJDPhase I trial of recombinant immunotoxin anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignanciesJ Clin Oncol20001881622163610764422
   PubMed Web of Science ®Google Scholar
• KreitmanRJSinghRStetler-StevensonMWaldmannTAPastanIRegression of adult T-cell leukemia with anti-CD25 recombinant immunotoxin LMB-2 preceded by chemotherapyBlood2011118212575
   Google Scholar
• ThorpePEWallacePMKnowlesPPNew coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivoCancer Res19874722592459313499221
   PubMedGoogle Scholar
• BellKDRamiloOVitettaESCombined use of an immunotoxin and cyclosporine to prevent both activated and quiescent peripheral blood T cells from producing type 1 human immunodeficiency virusProc Natl Acad Sci U S A1993904141114158434001
   PubMedGoogle Scholar
• WinklerUGottsteinCSchonGSuccessful treatment of disseminated human Hodgkin’s disease in SCID mice with deglycosylated ricin A-chain immunotoxinsBlood19948324664758286745
   PubMed Web of Science ®Google Scholar
• EngertAMartinGAmlotPWijdenesJDiehlVThorpePImmunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin a-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in miceInt J Cancer19914934504561917143
   PubMedGoogle Scholar
• EngertAGottsteinCWinklerUExperimental treatment of human Hodgkin’s disease with ricin A-chain immunotoxinsLeuk Lymphoma1994135–64414488069189
   PubMed Web of Science ®Google Scholar
• EngertADiehlVSchnellRA phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin’s lymphomaBlood19978924034109002941
   PubMed Web of Science ®Google Scholar
• SchnellRVitettaESchindlerJClinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin’s lymphomaLeuk Lymphoma1998305–65255389711915
   PubMed Web of Science ®Google Scholar
• SchnellRVitettaESchindlerJTreatment of refractory Hodgkin’s lymphoma patients with an anti-CD25 ricin A-chain immunotoxinLeukemia200014112913510637488
   PubMed Web of Science ®Google Scholar
• SchnellRBorchmannPStaakJOClinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin’s lymphomaAnn Oncol200314572973612702527
   PubMed Web of Science ®Google Scholar
• WeissALittmanDRSignal transduction by lymphocyte antigen receptorsCell19947622632748293463
   PubMed Web of Science ®Google Scholar
• CambierJCPleimanCMClarkMRSignal transduction by the B cell antigen receptor and its coreceptorsAnnu Rev Immunol19941214574868011288
   PubMedGoogle Scholar
• ScheuermannRHRacilaECD19 antigen in leukemia and lymphoma diagnosis and immunotherapyLeuk Lymphoma1995185–63853978528044
   PubMed Web of Science ®Google Scholar
• JuneCHCAR T cells for leukemia and moreCancer Res2012728 supplL1L3
   Google Scholar
• CoghlanANovel gene therapy cures leukaemia in eight daysNew Sci2013217291010
   Google Scholar
• ChungEYPsathasJNYuDLiYWeissMJThomas-TikhonenkoACD19 is a major B cell receptor–independent activator of MYC-driven B-lymphomagenesisJ Clin Invest201212262257226622546857
   PubMed Web of Science ®Google Scholar
• GrossbardMLFreedmanASRitzJSerotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusionBlood19927935765851370636
   PubMed Web of Science ®Google Scholar
• GoldmacherVSScottCFLambertJMCytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosisJ Cell Physiol198914112222342528553
   PubMedGoogle Scholar
• BlakeyDCSkilleterDNPriceRJThorpePEUptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivoBiochim Biophys Acta198896821721783257705
   PubMedGoogle Scholar
• BlakeyDCWatsonGJKnowlesPPThorpePEEffect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibodyCancer Res19874749479523492271
   PubMedGoogle Scholar
• GrossbardMLLambertJMGoldmacherVSAnti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasmsJ Clin Oncol19931147267377683045
   PubMed Web of Science ®Google Scholar
• StoneMJSausvilleEAFayJWA phase I study of bolus versus continuous infusion of the anti-CD19 immunotoxin, IgG-HD37-dgA, in patients with B-cell lymphomaBlood1996884118811978695836
   PubMed Web of Science ®Google Scholar
• CrockerPRClarkEAFilbinMSiglecs: a family of sialic-acid binding lectinsGlycobiology199882vvi9498912
   PubMedGoogle Scholar
• HattaYTsuchiyaNMatsushitaMShiotaMHagiwaraKTokunagaKIdentification of the gene variations in human CD22Immunogenetics199949428028610079291
   PubMedGoogle Scholar
• LiJ-LShenG-LGhetieM-AThe epitope specificity and tissue reactivity of four murine monoclonal anti-CD22 antibodiesCell Immunol1989118185992463099
   PubMedGoogle Scholar
• MansfieldEChironMFAmlotPPastanIFitzGeraldDJRecombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cellsBiochem Soc Trans19972527099191188
   PubMedGoogle Scholar
• MansfieldEAmlotPPastanIFitzGeraldDJRecombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumorsBlood1997905202020269292538
   PubMedGoogle Scholar
• KreitmanRJMarguliesIStetler-StevensonMWangQ-CFitzGeraldDJPastanICytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemiasClin Cancer Res2000641476148710778980
   PubMedGoogle Scholar
• KreitmanRJWangQ-CFitzGeraldDJPastanIComplete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4 (dsFv)-PE38 at doses tolerated by cynomolgus monkeysInt J Cancer199981114815510077166
   PubMedGoogle Scholar
• KreitmanRJWilsonWHBergeronKEfficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemiaN Engl J Med2001345424124711474661
   PubMed Web of Science ®Google Scholar
• KreitmanRJSquiresDRStetler-StevensonMPhase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignanciesJ Clin Oncol200523276719672916061911
   PubMed Web of Science ®Google Scholar
• KreitmanRJStetler-StevensonMMarguliesIPhase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemiaJ Clin Oncol200927182983299019414673
   PubMed Web of Science ®Google Scholar
• KreitmanRJPastanIAntibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotoxClin Cancer Res201117206398640522003067
   PubMed Web of Science ®Google Scholar
• WayneASKreitmanRJFindleyHWAnti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trialClin Cancer Res20101661894190320215554
   PubMed Web of Science ®Google Scholar
• SalvatoreGBeersRMarguliesIKreitmanRJPastanIImproved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage displayClin Cancer Res200284995100211948105
   PubMed Web of Science ®Google Scholar
• AldersonRFKreitmanRJChenTCAT-8015: a second-generation Pseudomonas exotoxin A–based immunotherapy targeting CD22-expressing hematologic malignanciesClin Cancer Res200915383283919188153
   PubMed Web of Science ®Google Scholar
• KreitmanRJTallmanMSRobakTPhase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemiaJ Clin Oncol201230151822182822355053
   PubMed Web of Science ®Google Scholar
• AronsEStetler-StevensonMWilsonWHFitzGeraldDJPPastanIPharmacokinetic analysis of response in hairy cell leukemia treated by anti-CD22 recombinant immunotoxin moxetumomab pasudotoxBlood2013122212871
   Web of Science ®Google Scholar
• KreitmanRJAronsETallmanMSHigh response rate of Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia includes eradication of minimal residual disease: potential importance for outcomeBlood2015126234161
   Google Scholar
• VitettaESStoneMAmlotPPhase I immunotoxin trial in patients with B-cell lymphomaCancer Res19915115405240581855219
   PubMed Web of Science ®Google Scholar
• AmlotPLStoneMJCunninghamDA phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapyBlood1993829262426338219217
   PubMedGoogle Scholar
• SausvilleEAHeadleeDStetler-StevensonMContinuous infusion of the anti-CD22 immunotoxin IgG-RFB4-SMPT-dgA in patients with B-cell lymphoma: a phase I studyBlood19958512345734657780133
   PubMedGoogle Scholar
• KreitmanRJImmunotoxins for targeted cancer therapyAAPS J200683E532E55117025272
   PubMed Web of Science ®Google Scholar
• PezzuttoADörkenBRabinovitchPSLedbetterJAMoldenhauerGClarkEACD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferationJ Immunol19871389279327992437199
   PubMedGoogle Scholar
• GhetieMAPickerLJRichardsonJATuckerKUhrJWVitettaESAnti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrestBlood1994835132913367509655
   PubMed Web of Science ®Google Scholar
• MessmannRAVitettaESHeadleeDA phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19 (+), CD22 (+) B cell lymphomaClin Cancer Res2000641302131310778955
   PubMed Web of Science ®Google Scholar
• HerreraLFarahRAPellegriniVAImmunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitroLeukemia200014585385810803517
   PubMed Web of Science ®Google Scholar
• HerreraLBostromBGoreLA phase 1 study of combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemiaJ Pediatr Hematol Oncol2009311293694119875969
   PubMed Web of Science ®Google Scholar
• SchindlerJGajavelliSRavandiFA phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia: combotox in Adult ALLBr J Haematol2011154447147621732928
   PubMed Web of Science ®Google Scholar
• SchwabUSteinHGerdesJProduction of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin’s disease and a subset of normal lymphoid cellsNature198229965677110326
   PubMed Web of Science ®Google Scholar
• AndreesenROsterholzJLohrGWBrossKJA Hodgkin cell-specific antigen is expressed on a subset of auto-and alloactivated T (helper) lymphoblastsBlood1984636129913026202342
   PubMedGoogle Scholar
• FaliniBPileriSPizzoloGCD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapyBlood19958517803786
   PubMed Web of Science ®Google Scholar
• SchwartingRGerdesJDurkopHFaliniBPileriSSteinHBER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitopeBlood1989745167816892477085
   PubMed Web of Science ®Google Scholar
• WileySRGoodwinRGSmithCAReverse signaling via CD30 ligandJ Immunol19961578363536398871664
   PubMedGoogle Scholar
• SchneixRLinnartzCKatouziAADevelopment of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigenInt J Cancer19956322382447591211
   PubMedGoogle Scholar
• SchnellRStaakOBorchmannPA phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4. dgA) in patients with refractory CD30+ Hodgkin’s and non-Hodgkin’s lymphomaClin Cancer Res2002861779178612060617
   PubMed Web of Science ®Google Scholar
• AndrewsRGTakahashiMSegalGMPowellJSBernsteinIDSingerJWThe L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursorsBlood1986685103010353768529
   PubMed Web of Science ®Google Scholar
• AndrewsRGTorok-StorbBBernsteinIDMyeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodiesBlood19836211241326190518
   PubMed Web of Science ®Google Scholar
• FreemanSDKelmSBarberEKCrockerPRCharacterization of CD33 as a new member of the sialoadhesin family of cellular interaction moleculesBlood1995858200520127718872
   PubMed Web of Science ®Google Scholar
• BernsteinIDSingerJWAndrewsRGTreatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressedJ Clin Invest1987794115311593470307
   PubMed Web of Science ®Google Scholar
• DeanATalpazMKantarjianHPhase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignanciesASCO Meet Abstr20102815_suppl6549
   Google Scholar
• ChoudharySMathewMVermaRSTherapeutic potential of anticancer immunotoxinsDrug Discov Today20111611–1249550321511052
   PubMed Web of Science ®Google Scholar
• BorthakurGRosenblumMGTalpazMPhase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignanciesHaematologica201398221722122875630
   PubMed Web of Science ®Google Scholar
• van AgthovenATerhorstCReinherzESchlossmanSCharacterization of T cell surface glycoproteins T1 and T3 present on all human peripheral T lymphocytes and functionally mature thymocytesEur J Immunol198111118216260508
   PubMedGoogle Scholar
• BorstJPrendivilleMATerhorstCComplexity of the human T lymphocyte-specific cell surface antigen T3J Immunol19821284156015656174606
   PubMedGoogle Scholar
• BorstJAlexanderSElderJTerhorstCThe T3 complex on human T lymphocytes involves four structurally distinct glycoproteinsJ Biol Chem19832588513551416220014
   PubMedGoogle Scholar
• FrankelAZuckeroSMankinAAnti-CD3 recombinant diphtheria immunotoxin therapy of cutaneous T cell lymphomaCurr Drug Targets200910210410919199905
   PubMed Web of Science ®Google Scholar
• MadhumathiJDevilakshmiSSrideviSVermaRSImmunotoxin therapy for hematologic malignancies: where are we heading?Drug Discov Today201621232533226049016
   PubMedGoogle Scholar
• FrankelALiuJ-SRizzieriDHoggeDPhase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasiaLeuk Lymphoma200849354355318297533
   PubMed Web of Science ®Google Scholar
• KreitmanRJPastanIRecombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either Pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cellsBlood19979012522599207460
   PubMedGoogle Scholar
• FrankelAEPowellBLHallPDCaseLDKreitmanRJPhase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemiaClin Cancer Res2002851004101312006512
   PubMed Web of Science ®Google Scholar
• ChangKPaiLHPassHMonoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinomaAm J Surg Pathol19921632592681599018
   PubMedGoogle Scholar
• HassanRLaszikZGLernerMRaffeldMPostierRBrackettDMesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitisAm J Clin Pathol2005124683884516416732
   PubMed Web of Science ®Google Scholar
• ArganiPIacobuzio-DonahueCRyuBMesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas identification of a new pancreatic cancer marker by Serial Analysis of Gene Expression (SAGE)Clin Cancer Res20017123862386811751476
   PubMed Web of Science ®Google Scholar
• OrdóñezNGApplication of mesothelin immunostaining in tumor diagnosisAm J Surg Pathol200327111418142814576474
   PubMed Web of Science ®Google Scholar
• HassanRKreitmanRJPastanIWillinghamMCLocalization of mesothelin in epithelial ovarian cancerAppl Immunohistochem Mol Morphol200513324324716082249
   PubMedGoogle Scholar
• TchouJWangL-CSelvenBMesothelin, a novel immunotherapy target for triple negative breast cancerBreast Cancer Res Treat2012133279980422418702
   PubMed Web of Science ®Google Scholar
• BabaKIshigamiSArigamiTMesothelin expression corre-lates with prolonged patient survival in gastric cancerJ Surg Oncol2012105219519921780126
   PubMed Web of Science ®Google Scholar
• EinamaTHommaSKamachiHLuminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancerBr J Cancer2012107113714222644300
   PubMed Web of Science ®Google Scholar
• ChangKPastanIWillnghamMCFrequent expression of the tumor antigen cak1 in squamous-cell carcinomasInt J Cancer19925145485541351045
   PubMedGoogle Scholar
• HoMBeraTKWillinghamMCMesothelin expression in human lung cancerClin Cancer Res20071351571157517332303
   PubMed Web of Science ®Google Scholar
• BeraTKPastanIMesothelin is not required for normal mouse development or reproductionMol Cell Biol20002082902290610733593
   PubMed Web of Science ®Google Scholar
• HassanRBullockSPremkumarAPhase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancersClin Cancer Res200713175144514917785569
   PubMed Web of Science ®Google Scholar
• KreitmanRJHassanRFitzGeraldDJPastanIPhase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1PClin Cancer Res200915165274527919671873
   PubMed Web of Science ®Google Scholar
• HassanRSharonEThomasAPhase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125Cancer2014120213311331924989332
   PubMed Web of Science ®Google Scholar
• VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321142636264412860938
   PubMed Web of Science ®Google Scholar
• HassanRMillerACSharonEMajor cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppressionSci Transl Med20135208208ra147
   PubMed Web of Science ®Google Scholar
• PaiLHBookmanMAOzolsRFClinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancerJ Clin Oncol1991912209521031960550
   PubMedGoogle Scholar
• PowellDJFelipe-SilvaAMerinoMJAdministration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivoJ Immunol200717974919492817878392
   PubMedGoogle Scholar
• OlayioyeMANeveRMLaneHAHynesNEThe ErbB signaling network: receptor heterodimerization in development and cancerEMBO J200019133159316710880430
   PubMed Web of Science ®Google Scholar
• YardenYSliwkowskiMXUntangling the ErbB signalling networkNat Rev Mol Cell Biol20012212713711252954
   PubMed Web of Science ®Google Scholar
• SlamonDGodolphinWJonesLStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancerScience198924449057077122470152
   PubMed Web of Science ®Google Scholar
• SchneiderPMHungM-CChioccaSMDifferential expression of the c-erbB-2 gene in human small cell and non-small cell lung cancerCancer Res19894918496849712569928
   PubMed Web of Science ®Google Scholar
• ParkJ-BRhimJSParkS-CKimmS-WKrausMHAmplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomasCancer Res19894923660566092573419
   PubMedGoogle Scholar
• PressMFCordon-CardoCSlamonDJExpression of the HER-2/neu proto-oncogene in normal human adult and fetal tissuesOncogene1990579539621973830
   PubMed Web of Science ®Google Scholar
• Pai-ScherfLHVillaJPearsonDHepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptorClin Cancer Res1999592311231510499598
   PubMedGoogle Scholar
• WelsWHarwerthI-MMuellerMGronerBHynesNESelective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptorCancer Res19925222631063171358432
   PubMedGoogle Scholar
• SpyridonidisASchmidtMBernhardtWPurging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxinsBlood1998915182018279473251
   PubMedGoogle Scholar
• SchmidtMMcWattersAWhiteRASynergistic Interaction between an anti-p185HER-2 Pseudomonas exotoxin fusion protein [scFv(FRP5)–ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2Gynecol Oncol200180214515511161852
   PubMedGoogle Scholar
• WangLLiuBSchmidtMLuYWelsWFanZAntitumor effect of an HER2-specific antibody–toxin fusion protein on human prostate cancer cellsProstate2001471212811304726
   PubMedGoogle Scholar
• WelsWBeerliRHellmannPEGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteinsInt J Cancer19956011371447814146
   PubMedGoogle Scholar
• AzemarMSchmidtMArltFRecombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivoInt J Cancer200086226927510738256
   PubMedGoogle Scholar
• AzemarMDjahansouziSJägerERegression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2Breast Cancer Res Treat200382315516414703062
   PubMed Web of Science ®Google Scholar
• HellströmIGarriguesHJGarriguesUHellströmKEHighly tumor-reactive, internalizing, mouse monoclonal antibodies to Ley-related cell surface antigensCancer Res1990507218321901690595
   PubMed Web of Science ®Google Scholar
• PaiLHWittesRSetserAWillinghamMCPastanITreatment of advanced solid tumors with immunotoxin LMB–1: an antibody linked to Pseudomonas exotoxinNat Med1996233503538612238
   PubMed Web of Science ®Google Scholar
• FriedmanPNMcAndrewSJGawlakSLBR96 sFv-PE40, a potent single-chain immunotoxin that selectively kills carcinoma cellsCancer Res19935323343398417827
   PubMedGoogle Scholar
• FriedmanPNChaceDFTrailPASiegallCBAntitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenograftsJ Immunol19931507305430618454873
   PubMedGoogle Scholar
• SiegallCBTargeted therapy of carcinomas using BR96 sFv-PE40, a single-chain immunotoxin that binds to the LeyantigenSemin Cancer Biol1995652892958562906
   PubMedGoogle Scholar
• PoseyJAKhazaeliMBBookmanMAA phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumorsClin Cancer Res20028103092309912374676
   PubMed Web of Science ®Google Scholar
• PuriRKLelandPKreitmanRJPastanIHuman neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric proteinInt J Cancer19945845745818056454
   PubMedGoogle Scholar
• LiuHPraysonRAEstesMLIn vivo eepression of the interleukin 4 receptor alpha by astrocytes in epilepsy cerebral cortexCytokine200012111656166111052816
   PubMedGoogle Scholar
• JoshiBHPlautzGEPuriRKInterleukin-13 receptor α chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomasCancer Res20006051168117210728667
   PubMed Web of Science ®Google Scholar
• PuriRKHoonDSLelandPPreclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytomaCancer Res19965624563156378971168
   PubMedGoogle Scholar
• HusainSRBehariNKreitmanRJPastanIPuriRKComplete regression of established human glioblastoma tumor xenograft by interleukin-4 toxin therapyCancer Res19985816364936539721874
   PubMedGoogle Scholar
• RandRWKreitmanRJPatronasNVarricchioFPastanIPuriRKIntratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade gliomaClin Cancer Res2000662157216510873064
   PubMed Web of Science ®Google Scholar
• WeberFAsherABucholzRSafety, tolerability, and tumor response of IL4-Pseudomonas exotoxin (NBI-3001) in patients with recurrent malignant gliomaJ Neurooncol2003641–212513712952293
   PubMed Web of Science ®Google Scholar
• BalzarMWinterMJde BoerCJLitvinovSVThe biology of the 17–1A antigen (Ep-CAM)J Mol Med1999771069971210606205
   PubMed Web of Science ®Google Scholar
• LitvinovSVBalzarMWinterMJEpithelial cell adhesion molecule (Ep-CAM) modulates cell–cell interactions mediated by classic cadherinsJ Cell Biol19971395133713489382878
   PubMedGoogle Scholar
• ZorzosJZiziABakirasAExpression of a cell surface antigen recognized by the monoclonal antibody AUA1 in bladder carcinoma: an immunohistochemical studyEur Urol1994283251254
   Google Scholar
• BrunnerAPrelogMVerdorferITzankovAMikuzGEnsingerCEpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladderJ Clin Pathol200861330731017586680
   PubMed Web of Science ®Google Scholar
• PaoloCDWilludaJKubetzkoSA recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activityClin Cancer Res2003972837284812855664
   PubMedGoogle Scholar
• KowalskiMEntwistleJCizeauJA phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patientsDrug Des Devel Ther20104313320
   PubMed Web of Science ®Google Scholar
• AlewineCHassanRPastanIAdvances in anticancer immunotoxin therapyOncologist201520217618525561510
   PubMed Web of Science ®Google Scholar
• YounesABartlettNLLeonardJPBrentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomasN Engl J Med2010363191812182121047225
   PubMed Web of Science ®Google Scholar
• VermaSMilesDGianniLTrastuzumab emtansine for HER2-positive advanced breast cancerN Engl J Med2012367191783179123020162
   PubMed Web of Science ®Google Scholar
• KreitmanRJHansenHJJonesALFitzGeraldDJPGoldenbergDMPastanIPseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab′ induce regression of subcutaneous human B-cell lymphoma in miceCancer Res19935348198258428363
   PubMedGoogle Scholar
• KuanCTPaiLHPastanIImmunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndromeClin Cancer Res1995112158915949815960
   PubMedGoogle Scholar
• BalunaRRizoJGordonBEGhetieVVitettaESEvidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndromeProc Natl Acad Sci U S A19999673957396210097145
   PubMedGoogle Scholar
• SmallshawJEGhetieVRizoJGenetic engineering of an immunotoxin to eliminate pulmonary vascular leak in miceNat Biotechnol200321438739112627168
   PubMed Web of Science ®Google Scholar
• WangHSongSKouGTreatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndromeCancer Immunol Immunother200756111775178317431617
   PubMed Web of Science ®Google Scholar
• WeldonJEXiangLZhangJA recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicityMol Cancer Ther2013121485723136186
   PubMedGoogle Scholar
• SchindlerJSausvilleEMessmannRVitettaESThe toxicity of deglycosylated ricin A chain-containing immunotoxins in patients with non-Hodgkin’s lymphoma is exacerbated by prior radiotherapy: a retrospective analysis of patients in five clinical trialsClin Cancer Res2001725525811234876
   PubMed Web of Science ®Google Scholar
• SiegallCBLiggittDChaceDTepperMAFellPHPrevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activityProc Natl Acad Sci U S A19949120951495187937798
   PubMedGoogle Scholar
• BüttelICChamberlainPChowersYTaking immunogenicity assessment of therapeutic proteins to the next levelBiologicals201139210010921353596
   PubMed Web of Science ®Google Scholar
• LeeJWKelleyMKingLEBioanalytical approaches to quantify “Total” and “Free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug developmentAAPS J20111319911021240643
   PubMed Web of Science ®Google Scholar
• BeraTKOndaMKreitmanRJPastanIAn improved recombinant Fab-immunotoxin targeting CD22 expressing malignanciesLeuk Res201438101224122925127689
   PubMedGoogle Scholar
• AlewineCXiangLYamoriTNiederfellnerGBossletKPastanIEfficacy of RG7787, a next-generation mesothelin-targeted immunotoxin, against triple-negative breast and gastric cancersMol Cancer Ther201413112653266125239937
   PubMed Web of Science ®Google Scholar
• BenharIPadlanEAJungS-HLeeBPastanIRapid humanization of the Fv of monoclonal antibody B3 by using framework exchange of the recombinant immunotoxin B3 (Fv)-PE38Proc Natl Acad Sci U S A1994912512051120557991583
   PubMedGoogle Scholar
• NagataSPastanIRemoval of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeuticsAdv Drug Deliv Rev2009611197798519679153
   PubMed Web of Science ®Google Scholar
• BirdREHardmanKDJacobsonJWSingle-chain antigen-binding proteinsScience198824248774234273140379
   PubMed Web of Science ®Google Scholar
• WardESGüssowDGriffithsADJonesPTWinterGBinding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coliNature198934162425445462677748
   PubMed Web of Science ®Google Scholar
• ReddyKRDevelopment and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD)Semin Liver DisNew York, NYThieme Medical Publishers, Inc200424333815346244
   PubMedGoogle Scholar
• GrahamMLPegaspargase: a review of clinical studiesAdv Drug Deliv Rev200355101293130214499708
   PubMed Web of Science ®Google Scholar
• MazorROndaMPastanIImmunogenicity of therapeutic recombinant immunotoxinsImmunol Rev2016270115216426864110
   PubMed Web of Science ®Google Scholar
• InadaYFurukawaMSasakiHBiomedical and biotechnological applications of PEG-and PM-modified proteinsTrends Biotechnol199513386917766222
   PubMed Web of Science ®Google Scholar
• LiuWOndaMLeeBRecombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopesProc Natl Acad Sci U S A201210929117821178722753489
   PubMedGoogle Scholar
• HollevoetKMason-OsannELiuXImhof-JungSNiederfellnerGPastanIIn vitro and in vivo activity of the low-immunogenic antimesothelin immunotoxin RG7787 in pancreatic cancerMol Cancer Ther20141382040204924928849
   PubMed Web of Science ®Google Scholar
• MazorREberleJAHuXRecombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopesProc Natl Acad Sci U S A2014111238571857624799704
   PubMedGoogle Scholar
• MazorRZhangJXiangLRecombinant immunotoxin with T-cell epitope mutations that greatly reduce immunogenicity for treatment of mesothelin-expressing tumorsMol Cancer Ther201514122789279626443804
   PubMed Web of Science ®Google Scholar
• OndaMBeersRXiangLNagataSWangQCPastanIAn immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopesProc Natl Acad Sci U S A200810532113111131618678888
   PubMed Web of Science ®Google Scholar